Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

POINT BIOPHARMA GLOBAL INC.

(PNT)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
7.380 USD   +2.22%
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Cancer; Shares Rise
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

POINT Biopharma Global Posts Wider Q3 Loss, Signs License Agreements With Lantheus; Shares Drop

11/14/2022 | 10:46am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
LANTHEUS HOLDINGS, INC. 0.64% 56.2 Delayed Quote.10.28%
POINT BIOPHARMA GLOBAL INC. 2.22% 7.38 Delayed Quote.1.23%
All news about POINT BIOPHARMA GLOBAL INC.
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for..
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Canc..
MT
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
01/12Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial
CI
01/12POINT Biopharma Global Inc. Completes Randomization in PNT2002’s Phase 3 SPLASH Tr..
CI
01/09Top Premarket Decliners
MT
2022Point Biopharma, Lantheus Close Licensing Deals for Cancer Treatment Candidates
MT
2022POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
AQ
2022Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements ..
CI
More news
Analyst Recommendations on POINT BIOPHARMA GLOBAL INC.
More recommendations
Financials (USD)
Sales 2022 47,3 M - -
Net income 2022 -50,8 M - -
Net cash 2022 274 M - -
P/E ratio 2022 -13,1x
Yield 2022 -
Capitalization 780 M 780 M -
EV / Sales 2022 10,7x
EV / Sales 2023 6,86x
Nbr of Employees 72
Free-Float 84,7%
Chart POINT BIOPHARMA GLOBAL INC.
Duration : Period :
POINT Biopharma Global Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POINT BIOPHARMA GLOBAL INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 7,38 $
Average target price 15,90 $
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Joe McCann Chief Executive Officer & Director
William Demers Chief Financial Officer
Allan C. Silber Executive Chairman
Neil E. Fleshner Chief Medical Officer & Director
Jessica Jensen Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
POINT BIOPHARMA GLOBAL INC.1.23%780
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008